Investor Relations LatestPress Releases Jan 04, 2023 Open Letter to Shareholders from CEO Paul Levesque Dec 01, 2022 Theratechnologies Announces Update from Ongoing TH1902 Study Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays btn News IR View All RecentEvents Oct 13, 2022 13 Oct 2022 at 8:30 AM EDT Third-Quarter Fiscal 2022 Financial Results Conference Call Listen to Webcast Sep 28, 2022 28 Sep 2022 at 9:00 AM EDT Cantor Oncology, Hematology & HemeOnc Conference Aug 10, 2022 10 Aug 2022 at 1:00 PM EDT Canaccord Genuity 42nd Annual Growth Conference Listen to webcast btn Events View All Financial InformationLatest Earnings Show all Q3 2022 Financial Statement 871 KB MD&A 397.9 KB btn QRs View More PresentationsInvestor Presentation Download PDF
Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Oct 13, 2022 13 Oct 2022 at 8:30 AM EDT Third-Quarter Fiscal 2022 Financial Results Conference Call Listen to Webcast
Aug 10, 2022 10 Aug 2022 at 1:00 PM EDT Canaccord Genuity 42nd Annual Growth Conference Listen to webcast